Indianapolis pharmaceutical giant Eli Lilly announced Monday that it has begun testing a potential antibody treatment for the coronavirus. The experimental drug was developed from a blood sample of one of America’s first COVID-19 patients.

According to Fox News the initial study involves 40 patients and results are expected by the end of June.

The first COVID-19 patients being treated with the therapy are hospitalized at New York’s Grossman School of Medicine in New York, Cedars-Sinai in Los Angeles and Emory Universe in Atlanta, according to CNN. The drug has been given a temporary name: LY-CoV555, said CNN.

“We take the very best one or two antibodies, and we scale them up and make them into a medicine,” Eli Lilly CEO David Ricks told Fox news, adding that it was “a very potent medicine.” Rick said the company has already begun production of the drug and could have 100,000 or more doses available by fall.